Articles by tag: targeted-therapy

Sunvozertinib outperforms chemotherapy in EGFR exon20ins lung cancer

NEJM: oral sunvozertinib reduces the risk of progression by 35% in NSCLC with EGFR exon20ins mutation. Full analysis of efficacy, toxicity and drug availability. Learn more.

ADC drugs against resistant small cell lung cancer: breakthrough 2026

New class of ADC drugs targets DLL3 and B7-H3, overcoming SCLC resistance. Analysis of efficacy, toxicity, and treatment prospects. Read more.

Proteomic Mapping of 28 Cancer Types: What You Need to Know

An international consortium has completed the first proteomic mapping of all 28 human cancer types. Learn about 13 new subtypes, targeted therapy, and the impact on oncology. Read more.

EMA approval of first-line treatment for aggressive colon cancer

EMA recommended encorafenib + cetuximab + FOLFOX for first-line BRAF V600E-mutant mCRC. 47% reduction in risk of progression. Read analysis and BREAKWATER study data.

Targeted therapy for ultra-rare blood cancer: FDA approves pivekimab sunirin

FDA has registered the first targeted therapy for BPDCN — pivekimab sunirin. Remission rate 69.7%, but there are risks. Detailed analysis of the drug and consequences.

Gedatolisib: Phase 3 success in PIK3CA-mutated cancer

Gedatolisib met the endpoint in the VIKTORIA-1 study, surpassing the standard of care. Learn how this will change the market. Read the detailed analysis.

A mechanism for overcoming drug resistance in cancer has been discovered

Scientists have found a way to sensitize head and neck cancer cells to death. The combination of b-AP15 and TRAIL causes the tumor to self-destruct through JNK signaling. Read about the breakthrough in oncology.

KRAS G12C colorectal cancer: sotorasib + panitumumab breakthrough

CodeBreak300 phase 3: Lumakras and Vectibix combination increased progression-free survival by 3 months. Treatment of KRAS G12C metastases approved. How dual blockade breaks 40-year resistance.

Role of XIAP protein in induction of death receptors in cancer

Scientists have found: suppression of XIAP protein opens death receptors DR5 on cancer cells. Learn how the combination of b-AP15 and TRAIL forces the tumor to self-destruct through apoptosis.